The treatment method of persistent macula edema after phaco-vitrectomy

Purpose. To show the result of treatment of persistent macular edema as complication of chronic uveitis after phaco-vitrectomy. Material and methods. At this clinical case we show the results of treatment one patient, who was treated at the ophthalmological clinic «EYE Doctor», Almaty, Kazakhstan. He had complication of chronic uveitis as persistent macular edema after phaco-vitrectomy. The complex treatment (instillation of non-steroid anti-inflammation drops and subtenon injection of diprospan) was unsuccessful. Results. The result of treatment is successful; we get stable decrease of severity of cystoid macular edema and stabilization of visual acuity. Conclusion: This method allows to decrease the cystoid macular edema and to stable the visual acuity. It helps us to treat the patients, when other methods are unsuccessful and there is no financial possibility for treatment with intravitreal injection «Ozurdex». Key words: persistent macular edema, chronic uveitis, Diprospan, intravitreal injection.

To compare peribulbar and subtenon anaesthesia in patients undergoing cataract surgery

To compare peribulbar and subtenon anaesthesia in patients undergoing cataract surgery. In a hospital based randomised comparative interventional study, patients who underwent cataract surgery were randomised into two groups, one receiving peribulbar and the other subtenon anaesthesia. Pain during administration, pain during surgery, chemosis, subconjunctival haemorrhage globe akinesia were noted and compared in the two groups. Any other complications which occur also noted. The pain during administration was significantly lesser in subtenon injection as compared to peribulbar anaesthesia. Pain during surgery was comparable in the two groups. Incidence of subconjunctival haemorrhage and chemosis was more in subtenon injection as compared to peribulbar anaesthesia. Globe akinesia was achieved more effectively in subtenon injection as compared to peribulbar injection. The subtenon anaesthesia is comparable to peribulbar anaesthesia with few additional advantages and is recommended as safe and effective alternative to peribulbar anaesthesia for cataract surgery.

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy

We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). We analyzed consecutive 42 eyes of 40 patients with treatment-naïve nAMD associated with type 1 CNV. Three monthly injections of brolucizumab were completed in 36 eyes (85.7%). In those cases, best-corrected visual acuity (BCVA) was 0.24 ± 0.27 at baseline and improved significantly to 0.12 ± 0.23 after 3 months (P < 0.001). Central macular thickness was 301 ± 110 µm at baseline and decreased significantly to 160 ± 49 µm after 3 months (P < 0.001). Dry macula was achieved in 34 eyes (94.4%) after the loading phase. Central choroidal thickness was 264 ± 89 µm at baseline and decreased significantly to 223 ± 81 µm after 3 months (P < 0.001). Indocyanine green angiography after the loading phase revealed complete regression of polypoidal lesions in 15 of the 19 eyes (78.9%) with polypoidal lesions. Non-infectious intraocular inflammation (IOI) was observed in 8 of 42 eyes (19.0%) during the loading phase, while showing amelioration in response to combination therapy with topical and subtenon injection of steroids. In these eyes, BCVA after 3 months had not deteriorated as compared to that at baseline. These results indicate that loading phase treatment with intravitreal brolucizumab might be effective for improving visual acuity and reducing exudative changes in eyes with nAMD associated with type 1 CNV. Moreover, polypoidal lesions appear to frequently regress after this treatment. However, we must monitor patients carefully for brolucizumab-related IOI, and administer steroid therapy promptly.

Outcome of Trabeculectomy with Intraoperative Subtenon Injection of Mitomycin C

Purpose: To evaluate the efficacy of trabeculectomy with intraoperative subtenon injection of Mitomycin C (MMC) in terms of control of Intraocular pressure post-operatively.Study design: Observational studyMethods: A total of 49 patient’s medical records who underwent trabeculectomy with intraoperative subtenon injection of MMC with diagnosis of Primary Open Angle Glaucoma (POAG) from January 2017 to December 2018 were evaluated to see the post-operative outcomes in terms of control of intraocular pressure (IOP) with 12 months follow-up. The medical records were retrieved using the hospital information system. Age, gender, pre-operative IOP, Best-Corrected Visual Acuity (BCVA), co-morbids, previous surgery, Central Corneal Thickness (CCT), fundus findings, number of glaucoma medications and postoperative complications were obtained by using a proforma.Results: Total 72 eyes of 49 patient records were evaluated to see post operative outcomes at three, six and twelve months follow up. The mean IOP preoperatively was 24.68±13.66 mm Hg with maximum anti-glaucoma treatment. After the surgery the mean IOP was 13.69±6.68 mmHg at 3 months follow-up, and 12.68±4.04 and 13.33±4.8 mmHg at 6 and 12 months respectively (P-value 0.001). Preoperatively mean CCT was 529.81±28.75 and at 12 months follow-up after surgery was 530.45±29.43 with P-value 0.245. Best Corrected Visual Acuity outcomes were seen at each follow-up and results were found to be statistically significant (P value ≤ 0.05).Conclusions: Twelve months follow-up of trabeculectomy show that intraoperative subtenon injection of MMC is effective in terms of control of IOP postoperatively with minimal complications in patients with POAG.

The effectiveness of subtenon triamcinolone injection for the treatment of macular edema in children with retinitis pigmentosa

Aim: This study aimed to assess the functional and anatomical results of subtenon triamcinolone injections in children with retinitis pigmentosa (PR) and cystic macular edema (CME), refractory to local carbonic anhydrase inhibitors. Material and methods: We examined 11 children (9 girls, 2 boys) aged 9 to 17 years who underwent subtenon injections of triamcinolone (22 eyes). The follow-up period ranged from 1.6 to 33.1 months (average 9.711.6 months), the number of triamcinalone injections ranged from 1 to 11, averaging 3. Before and after injection, best corrected visual acuity (BCVA), the thickness and structure of the retina in the macular zone (optical coherence tomography [OCT] was performed by using the NIDEK RS-3000, Japan or the Spectralis, Heidelberg Engineering, Germany), and intraocular pressure (IOP) were assessed. Results: The CME height at the end of the observation period decreased in 10 cases (45.5%), and the average central retinal thickness decreased from 70 to 594 m (on average, 219.1183.4 m). In 12 eyes (54.5%), the CME height at the end of the observation period did not change significantly. BCVA improved in two eyes (9.1%) and did not change in the other cases. Two children (18%) developed ophthalmic hypertension in both eyes after two injections of triamcinalone. In one child, IOP returned to normal on the background of hypothetical therapy. In another child, due to non-compensation of IOP at the maximum hypotensive mode, sinus trabeculectomy was performed in both eyes, and IOP normalization was achieved. Conclusion: Subtenon injection of triamcinolone in children with CME against a background of PR is in most cases is an effective and safe method of treatment and can be recommended if carbonic anhydrase inhibitors are ineffective at reducing/ resorbing edema and maintaining or improving visual function. Considering that the action of triamcinolone is short lived, and its repeated injection is required, and the resorption of CME and an increase in visual acuity are not always achievable, it is necessary to continue the search for more effective treatment methods.

Treatment of resistant chronic central serous chorioretinopathy via platelet-rich plasma with electromagnetic stimulation

Background: To evaluate whether subtenon injection of platelet-rich plasma (PRP) with retinal electromagnetic stimulation (rEMS) is effective in therapy-resistant chronic central serous chorioretinopathy (CSCR). Design: Prospective, sequential. Materials & methods: The study included 22 eyes with resistant chronic CSCR. Cases receiving micropulse laser or additional photodynamic therapy, subtenon PRP, and subtenon PRP + rEMS were classified as times 1, 2 and 3, respectively. Results: At time 3, the mean best-corrected visual acuity was 85.7 and 97.0 letters before and after the procedures, respectively (p = 0.01). Submacular thickness improved by 17, 27 and 51% at times 1, 2 and 3 respectively. Conclusion: For treating resistant CSCR, subtenon PRP + rEMS should be considered as an effective and safe option. Trial Registration: ClinicalTrials.gov ID: NCT04224831